[go: up one dir, main page]

RS58688B1 - Formulacije (s)-3-(4-((4-(morfolinometil)benziloksi)-1-oksoizoindolin-2-il)piperidin-2,6-diona - Google Patents

Formulacije (s)-3-(4-((4-(morfolinometil)benziloksi)-1-oksoizoindolin-2-il)piperidin-2,6-diona

Info

Publication number
RS58688B1
RS58688B1 RS20190490A RSP20190490A RS58688B1 RS 58688 B1 RS58688 B1 RS 58688B1 RS 20190490 A RS20190490 A RS 20190490A RS P20190490 A RSP20190490 A RS P20190490A RS 58688 B1 RS58688 B1 RS 58688B1
Authority
RS
Serbia
Prior art keywords
oxoisoindolin
morpholinomethyl
benzyloxy
dione
piperidine
Prior art date
Application number
RS20190490A
Other languages
English (en)
Inventor
Darshan Parikh
Anil Menon
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of RS58688B1 publication Critical patent/RS58688B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
RS20190490A 2013-10-08 2014-10-07 Formulacije (s)-3-(4-((4-(morfolinometil)benziloksi)-1-oksoizoindolin-2-il)piperidin-2,6-diona RS58688B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361888419P 2013-10-08 2013-10-08
PCT/US2014/059424 WO2015054199A1 (en) 2013-10-08 2014-10-07 Formulations of (s)-3-(4-((4-(morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
EP14786429.2A EP3054927B1 (en) 2013-10-08 2014-10-07 Formulations of (s)-3-(4-((4-(morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione

Publications (1)

Publication Number Publication Date
RS58688B1 true RS58688B1 (sr) 2019-06-28

Family

ID=51743584

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20190490A RS58688B1 (sr) 2013-10-08 2014-10-07 Formulacije (s)-3-(4-((4-(morfolinometil)benziloksi)-1-oksoizoindolin-2-il)piperidin-2,6-diona

Country Status (35)

Country Link
US (2) US10080801B2 (sr)
EP (1) EP3054927B1 (sr)
JP (1) JP6562907B2 (sr)
KR (1) KR102272274B1 (sr)
CN (1) CN105899196B (sr)
AR (1) AR100663A1 (sr)
AU (1) AU2014332171C1 (sr)
BR (1) BR112016007729B1 (sr)
CA (1) CA2921436C (sr)
CL (1) CL2016000816A1 (sr)
CR (1) CR20160131A (sr)
CY (1) CY1121689T1 (sr)
DK (1) DK3054927T3 (sr)
EA (1) EA032421B1 (sr)
ES (1) ES2723891T3 (sr)
HR (1) HRP20190733T1 (sr)
HU (1) HUE044186T2 (sr)
IL (1) IL244494B (sr)
LT (1) LT3054927T (sr)
MX (1) MX2016004342A (sr)
NI (1) NI201600048A (sr)
NZ (1) NZ716856A (sr)
PE (1) PE20160550A1 (sr)
PH (1) PH12016500301A1 (sr)
PL (1) PL3054927T3 (sr)
PT (1) PT3054927T (sr)
RS (1) RS58688B1 (sr)
SA (1) SA516370860B1 (sr)
SG (1) SG11201600996UA (sr)
SI (1) SI3054927T1 (sr)
SM (1) SMT201900231T1 (sr)
TR (1) TR201905874T4 (sr)
TW (1) TW201605493A (sr)
UA (1) UA117141C2 (sr)
WO (1) WO2015054199A1 (sr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012009237A (es) 2010-02-11 2012-08-23 Celgene Corp Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos.
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
ES2800026T3 (es) 2012-08-09 2020-12-23 Celgene Corp Tratamiento de enfermedades inmunitarias e inflamatorias
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
TWI794885B (zh) 2014-05-19 2023-03-01 美商西建公司 全身紅斑性狼瘡之治療
ITUB20160650A1 (it) * 2016-02-11 2017-08-11 Dipharma S A Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione
US11529339B2 (en) 2018-10-01 2022-12-20 Celgene Corporation Combination therapy for the treatment of cancer
SG11202107438WA (en) * 2019-01-09 2021-08-30 Celgene Corp Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
WO2021092498A1 (en) 2019-11-07 2021-05-14 Juno Therapeutics, Inc. Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4 ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]- piperidine-2,6-dione
BR112022026090A2 (pt) * 2020-06-25 2023-01-17 Celgene Corp Métodos para tratar câncer com terapias de combinação
CN115776909A (zh) * 2020-07-17 2023-03-10 美国杰龙生物医药公司 皮下端粒酶抑制剂组合物及其使用方法
WO2024064646A1 (en) 2022-09-20 2024-03-28 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
IT1274549B (it) 1995-05-23 1997-07-17 Indena Spa Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
CN1511420A (zh) 2001-11-09 2004-07-07 松下电器产业株式会社 运动图像编码方法和装置
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
KR101224262B1 (ko) 2004-03-22 2013-01-21 셀진 코포레이션 면역조절 화합물을 포함하는 피부 질환 또는 장애의 치료및 관리용 조성물 및 이의 사용 방법
ZA200609226B (en) 2004-04-23 2008-06-25 Celgene Corp Methods of using and compositions comprising immuno-modulatory compounds for the treatment and management of pulmonary hypertension
MX2007005570A (es) 2004-11-12 2007-07-09 Celgene Corp Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos.
MX2007006063A (es) 2004-11-23 2007-07-11 Celgene Corp Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de lesion al sistema nervioso central.
PL2380887T3 (pl) 2005-06-30 2014-01-31 Celgene Corp Sposób wytwarzania związków 4-amino-2-(2,6-diokso-piperydyn-3-ylo)izoindolino-1,3-dionu
CA2822094C (en) 2005-08-31 2015-10-27 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
ES2426350T3 (es) 2006-08-30 2013-10-22 Celgene Corporation Compuestos de isoindolina sustituidos en 5
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
PL2076260T3 (pl) 2006-09-15 2011-08-31 Celgene Corp Związki N-metyloaminometylo-izoindolu, kompozycje zawierające te związki, oraz metody ich stosowania
SI2066656T1 (sl) 2006-09-26 2012-06-29 Celgene Corp Zamenjani derivati kinazolinona kot protitumorska sredstva
CN103641814A (zh) 2007-03-20 2014-03-19 细胞基因公司 4’-o-取代的异吲哚啉衍生物和包含它的组合物及使用方法
BRPI1007855B1 (pt) 2009-05-19 2020-03-10 Celgene Corporation Formas de dosagem oral compreendendo 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolina-1,3-diona
MX2012009237A (es) * 2010-02-11 2012-08-23 Celgene Corp Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos.

Also Published As

Publication number Publication date
SG11201600996UA (en) 2016-03-30
HRP20190733T1 (hr) 2019-06-14
JP6562907B2 (ja) 2019-08-21
IL244494A0 (en) 2016-04-21
CN105899196B (zh) 2020-02-14
KR102272274B1 (ko) 2021-07-05
CA2921436A1 (en) 2015-04-16
SI3054927T1 (sl) 2019-06-28
BR112016007729A2 (sr) 2017-08-01
CA2921436C (en) 2022-01-04
PH12016500301A1 (en) 2016-05-02
AU2014332171B2 (en) 2019-09-12
JP2016532657A (ja) 2016-10-20
CY1121689T1 (el) 2020-07-31
MX2016004342A (es) 2016-07-05
EP3054927B1 (en) 2019-02-20
EA201690741A1 (ru) 2016-07-29
NI201600048A (es) 2016-05-20
TW201605493A (zh) 2016-02-16
US10080801B2 (en) 2018-09-25
UA117141C2 (uk) 2018-06-25
AU2014332171C1 (en) 2020-03-26
HUE044186T2 (hu) 2019-10-28
EA032421B1 (ru) 2019-05-31
CL2016000816A1 (es) 2017-03-10
PE20160550A1 (es) 2016-05-21
TR201905874T4 (tr) 2019-05-21
PL3054927T3 (pl) 2019-08-30
ES2723891T3 (es) 2019-09-03
PT3054927T (pt) 2019-05-29
LT3054927T (lt) 2019-07-10
USRE49647E1 (en) 2023-09-12
IL244494B (en) 2020-05-31
DK3054927T3 (da) 2019-05-13
WO2015054199A8 (en) 2016-05-06
BR112016007729B1 (pt) 2023-05-16
AU2014332171A1 (en) 2016-04-14
EP3054927A1 (en) 2016-08-17
SMT201900231T1 (it) 2019-07-11
KR20160067118A (ko) 2016-06-13
US20150099745A1 (en) 2015-04-09
AR100663A1 (es) 2016-10-26
CN105899196A (zh) 2016-08-24
WO2015054199A1 (en) 2015-04-16
SA516370860B1 (ar) 2018-08-14
NZ716856A (en) 2021-12-24
CR20160131A (es) 2016-07-27

Similar Documents

Publication Publication Date Title
SG11201600996UA (en) Formulations of (s)-3-(4-((4-(morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
HK1211576A1 (en) Salts and solid forms of (s) -3-(4-((4-morpholinomethyl)benzyl)oxy)- 1-oxoisoindolin-2-yl) piperidine-2,6-dione and compositions comprising and methods of using the same (s)-3-(4-((4-()))-1--2-)-26-
IL248546A0 (en) A polysubstituted fluorine compound as a proton tyrosine kinase inhibitor
HK1211489A1 (en) Methods of treating cancer using 3-(4-((4- (morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6- dione 3-(4-((4-)))-1--2-)-2 6-
IL251818A0 (en) Crystal forms of 5-chloro-ene 4-[2-(dimethylphosphoryl)phenyl]-ene 2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidin-2- 4-diamine
HK1211577A1 (en) Processes for the preparation of (s)-3-4- ((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof (s)-3-(4-((4-()))-1--2-)- 26-
ZA201701132B (en) Novel 2,5-substituted pyrimidines as pde inhibitors
SG11201508836XA (en) Synthesis of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2,6-dione
IL240197B (en) Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one
GB2558498B (en) Novel levothyroxine formulations for oral use
HK1252415A1 (zh) 包含3-(5-氨基-2-甲基-4-氧代基-4h-喹唑啉-3-基)-呱啶-2,6-二酮的藥物組合物
TH1501006617A (th) การสังเคราะห์ 3-(5อะมิโน-2-เมธิล-4-ออกโซควินาโซลิน-3(4h)-อิล)ไพเพอริดีน-2,6-ไดโอน
TH1501000645A (th) เกลือและรูปของแข็งของ(s)-3-(4-((4-มอร์ฟอลิโนเมธิล)เบนซิล)ออกซิ)-1-ออกโซไอโซอินโดลิน-2-อิล)ไพเพอริดีน-2,6-ไดโอน และองค์ประกอบซึ่งประกอบรวมด้วย และวิธีของการใช้สารเดียวกัน